Serum C4 levels in patients with systemic lupus erythematosus in remission

References

• Cooper NR. The complement system. In: Stites DP, Stobo JD, Wells JV, editors. Basic and clinical immunology. 6th ed. East Norwalk: Appleton and Lange; 1987. p. 114–27.
   Google Scholar
• Appel AE, Sablay LB, Golden RA, Barland P, Grayzel AL, Bank N. The effect of normalization of serum complement and anti-DNA antibody on the course of lupus nephritis. Am J Med 1978;64:274–83.
   PubMed Web of Science ®Google Scholar
• Tomooka K, Yasuda M, Sakai K, Suenaga Y, Nonaka S, Nobunaga M. In vivo complement activation influencing complement profiles of rheumatoid arthritis patients without extra-articular symptoms. Jpn J Ftheumatol 1994;5:129–37.
   Google Scholar
• Senaldi G, Mrknde VA, Vergani D, Isenberg DA. Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus. Ann Rheum Dis 1988;47:913–7.
   PubMedGoogle Scholar
• Kerr LD, Adelsberg BR, Schulman P, Spiera H. Factor B activa-tion products in patients with systemic lupus erythematosus. A marker of severe disease activity. Arthritis Rheum 1989;32:1405–13.
   Google Scholar
• Howard PF, Hochberg MC, Bias WB, Arnett FC, Mclean RH. Relationship between C4 null genes, HLA-D region antigens, and genetic susceptibility to systemic lupus erythematosus in Caucasians and Black Americans. Am J Med 1986;81: 187–93.
   Google Scholar
• Yamada H, Watanabe A, Mimori A, Nakano K, Takeuchi F, Matsuda K, et al. Lack of gene deletion for complement C4A deficiency in Japanese patients with systemic lupus erythematosus. J Ftheumatol 1990;17:1054–7.
   Google Scholar
• Petri M, Watson R, Winkelstein JA, McLean RH. Clinical ex-pression of systemic lupus erythematosus in patients with C4A deficiency. Medicine 1993;72:236–44.
   PubMedGoogle Scholar
• Davies EJ, Steers G, Oilier WER, Grennan DM, Cooper RG, Hay EM, et al. Relative contributions of HLA-DQA and complement C4A loci in determining susceptibility to systemic lupus erythema-tosus. Br J Ftheumatol 1995;34:221–5.
   PubMedGoogle Scholar
• Dragon-Durey MA, Rougier N, Clauvel JP, Caillat-Zucman S, Remy P, Guillevin L, et al. Lack of evidence of a specific role for C4A gene deficiency in determining disease susceptibility among C4-deficient patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 2001;123: 133–9.
   Google Scholar
• Miura N, Prentice H, Schneider PM, Perlmutter DH. Synthesis and regulation of the two human complement C4 genes in stable transfected mouse fibroblasts. J Biol Chem 1987;262:7298–305.
   PubMedGoogle Scholar
• Kulies JK, Cotten HR, Perlmutter DH. Counter regulatory effects of interferon-y and endotoxin on expression of the human C4 genes. J Clin Invest 1990;85: 943–9.
   Google Scholar
• Morgan BP, Gasque P. Extrahepatic complement biosynthesis: where, when and why? Clin Exp Immunol 1997;107:1–7.
   PubMedGoogle Scholar
• Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Tothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.
   PubMed Web of Science ®Google Scholar
• Tsukamoto H, Nagasawa K, Ueda Y, Mayumi T, Yoshizawa S, Furugo I, et al. Effects of T cells on the complement production by monocytes. Cell Immunol 1993;146:382–90.
   PubMedGoogle Scholar
• Sim E, Cross SJ. Phenotyping of human complement component C4, a class-III HLA antigen. Biochem J 1986;239:763–7.
   PubMed Web of Science ®Google Scholar
• Mauff G, Brenden M, Braun-Stilwell M, Doxiadis G, Giles CM, Hauptmann G, et al. C4 reference typing report. Complement Inflamm 1990;7: 193–212.
   Google Scholar
• Liang M, Socher SA, Larson M, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107–18.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992;35:630–40.
   PubMed Web of Science ®Google Scholar
• Charlesworth JA, Peake PW, Golding J, Mackie JD, Pussell BA, Timmermans V, et al. Hypercatabolism of C3 and C4 in active and inactive systemic lupus erythematosus. Ann Rheum Dis 1989;48: 153–9.
   PubMedGoogle Scholar
• Via CS, Handwerger BS. B-cell and T-cell function in systemic lupus erythematosus. Curr Opin Ftheumatol 1993;5:570–4.
   PubMedGoogle Scholar
• Alcocer-Varela J, Alarcon-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 1982;69: 1388–92.
   PubMed Web of Science ®Google Scholar
• Csiszar A, Nagy GY, Gergely P, Pozsonyi T, Pocsik E. Increased interferon-gamma (IFN-y), IL-10 and decreased IL-4 mFtNA expression in peripheral blood mononuclear cells (BPMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 2000;122: 464–70.
   Google Scholar
• Sakane T, Murakawa Y, Suzuki N, Ueda Y, Tsuchida T, Takada S, et al. Familial occurrence of unpaired interleukin-2 activity and increased peripheral blood B cells actively secreting immunoglo-bulins in systemic lupus erythematosus. Am J Med 1989;86:385–90.
   PubMed Web of Science ®Google Scholar
• Murakawa Y, Sakane T. Deficient phytohemagglutinin-induced interleukin-2 activity in patients with inactive systemic lupus erythematosus is correctable by the addition of phorbol myristate acetate. Arthritis Rheum 1989;31:826–33.
   Google Scholar
• Crabtree GR, Gillis S, Smith KA, Munck A. Glucocorticoid and immune responses. Arthritis Rheum 1979;22:1246–56.
   PubMedGoogle Scholar